Cognition
Phosphodiesterase type 5 inhibitors enhance cognitive abilities
Published in Medical Letter on the CDC and FDA, December 25th, 2005
According to a report from the United States, "Drug development for the treatment of dementia and age-related cognitive decline has been slow to produce clinically viable alternatives to the two existing FDA-approved drug treatments, AChE inhibitors and the noncompetitive NMDA receptor antagonist, memantine. Recent human and preclinical animal studies suggest that phosphodiesterase type 5 (PDE5) inhibitors, already in clinical use for the treatment of erectile dysfunction in men, may have central cognitive enhancing effects."
"Recent behavioral pharmacological studies with rodents...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Dengue Virus
Fourplex real-time RT-PCR assay to detect dengue viruses is developed - Measles Vaccine
More sclerosing panencephalitis prevented by measles vaccine than previously recognized - Rotavirus Vaccine
Vaccination reduces disease burden and health costs of rotavirus diarrhea in Vietnam - Smallpox Vaccine
Maxi-Vac software aids in planning mass smallpox vaccination clinics - Vaccine Registries
Electronic billing systems need improvement to maintain accurate vaccine registries - Acinetobacter Baumannii
Integrons are useful markers for epidemic strains of Acinetobacter baumannii - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
